Application Note | April 2, 2024
Cell Surface Proteomics for ADC Development: Deep Profiling of TAAs
Get the Resource
Download NowAntibody-drug conjugates (ADCs) are a promising new class of cancer therapeutics, offering a powerful combination of specificity and potency via targeted delivery of cytotoxic agents to tumor cells. The antibody component of the ADC enables selective recognition of and binding to cell surface tumor-associated antigens (TAAs) within the tumor, allowing the drug payload to be delivered directly into the cancer cell. How can cell surface proteomics advance these precision therapies?
The cell surface proteome serves as a rich source of potential therapeutic targets for ADCs. Comprehensive characterization of cell surface TAAs is among the most important criteria in developing ADC therapies, as efficacy and safety depends on the optimization of an ADC binding to its target.
Explore how Sapient’s /Deep/ Cell Surface Proteomics approach enables comprehensive cell surface proteomics, with measure of up to 1,000 well defined cell surface proteins to identify and target TAAs that are differentially and abundantly expressed on tumors compared to healthy tissues. Our workflow is enabled by Evosep liquid chromatography coupled to Bruker timsTOF HT mass spectrometers, which achieve deep proteome coverage and high confidence identification of proteins and PTMs via direct peptide sequencing.
Download the Application Note to learn the technical details of our method for cell surface proteomics, and how it can be applied to advance ADC development through the identification and characterization of TAAs, including discovery of novel TAAs for ADC targeting.
In fact, Sapient can rapidly perform global proteomic experiments or can selectively enrich cell surface proteins to screen different cell lines, tissues and tumors, within and across different cell lines and tumor samples. Importantly, our workflow not only provides information on the abundance of 1,000 surface proteins but can also inform on their copy numbers. Quantification of protein copy numbers within and across indications helps to nominate TAAs as attractive targets for ADC development.
Through deep surface protein profiling and quantitative insights, our platform empowers informed decision-making in TAA selection, ultimately driving the optimization of ADCs for enhanced efficacy and safety in cancer therapy.
